SEC Form 4

FORM 4		UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940	OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response: 0.5
	Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
	Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person* SCHWARTZ NORMAN D (Last) (First) (Middle) C/O BIO-RAD LABORATORIES, INC. 1000 ALFRED NOBEL DRIVE (Street) HERCULES CALIFORNIA 94547 (City) (State) (Zip) UNITED STATES (Country)	2. Issuer Name and Ticker or Trading Symbol BIO-RAD LABORATORIES, INC. [ BIO BIO.B ]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director X 10% Owner X Officer (give title below) Other (specify below) Chairman & CEO
	2a. Foreign Trading Symbol
	3. Date of Earliest Transaction (Month/Day/Year) 09/01/2026	6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person
	4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Bio-Rad A Common Stock	09/01/2026		M		5,087(1)	A	$0	448,521	D
Bio-Rad A Common Stock	09/01/2026		F		2,336	D	$380.96	446,185	D
Bio-Rad B Common Stock								361,466	D
Bio-Rad B Common Stock								13,006	I	By Spouse(2)
Bio-Rad B Common Stock								4,060,054	I	By Blue Raven Partners, L.P.(3)
Bio-Rad A Common Stock								1,781,356	I	By Alice N. Schwartz Revocable Trust(4)
Bio-Rad A Common Stock								90	I	By David Schwartz Exemption Trust(4)
Bio-Rad A Common Stock								240	I	By David Schwartz Exempt Martial Trust(4)
Bio-Rad A Common Stock								898,931	I	By David Schwartz Non-Exempt Martial Trust(4)
Bio-Rad B Common Stock								57,000	I	By David Schwartz Non-Exempt Martial Trust(4)
Bio-Rad A Common Stock								34,311	I	By Charitable Remainder Unitrust(4)
Bio-Rad B Common Stock								437,510	I	By Alice N. Schwartz Revocable Trust(4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(5)	09/01/2026		M			2,082	(6)	(6)	Bio-Rad A Common Stock	2,082	$0	0	D
Restricted Stock Units	$0(5)	09/01/2026		M			3,005	(7)	(7)	Bio-Rad A Common Stock	3,005	$0	3,005	D

Explanation of Responses:

1. Shares of Class A common stock acquired on the vesting of restricted stock units.

2. The reporting person disclaims beneficial ownership of these shares.

3. The shares are held by a limited partnership of which the reporting person is a limited and general partner. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

4. The shares are held by in trust of which the reporting person serves as the trustee. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.

5. Each restricted stock unit represents a contingent right to receive one share of Bio-Rad Class A common stock.

6. On September 1, 2022, the reporting person was granted 8,326 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

7. On September 1, 2023, the reporting person was granted 12,020 restricted stock units, vesting in four equal annual installments beginning on the first anniversary of the grant date.

Remarks:

	/s/ Norman Schwartz	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)